Meyer Zu Schwabedissen HE - Search Results

1

Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data.

Huynh C, Seeland S, Segrestaa J, Gnerre C, Hogeback J, Meyer Zu Schwabedissen HE, Dingemanse J, Sidharta PN. Huynh C, et al. Among authors: meyer zu schwabedissen he. Front Pharmacol. 2022 Mar 30;13:812065. doi: 10.3389/fphar.2022.812065. eCollection 2022. Front Pharmacol. 2022. PMID: 35431953 Free PMC article.

2

Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions.

Huynh C, Dingemanse J, Meyer Zu Schwabedissen HE, Sidharta PN. Huynh C, et al. Among authors: meyer zu schwabedissen he. Pharmacol Res. 2020 Nov;161:105092. doi: 10.1016/j.phrs.2020.105092. Epub 2020 Aug 3. Pharmacol Res. 2020. PMID: 32758634 Free article. Review.

3

A Multipurpose First-in-Human Study With the Novel CXCR7 Antagonist ACT-1004-1239 Using CXCL12 Plasma Concentrations as Target Engagement Biomarker.

Huynh C, Henrich A, Strasser DS, Boof ML, Al-Ibrahim M, Meyer Zu Schwabedissen HE, Dingemanse J, Ufer M. Huynh C, et al. Among authors: meyer zu schwabedissen he. Clin Pharmacol Ther. 2021 Jun;109(6):1648-1659. doi: 10.1002/cpt.2154. Epub 2021 Feb 15. Clin Pharmacol Ther. 2021. PMID: 33406277

4

Target engagement of the first-in-class CXCR7 antagonist ACT-1004-1239 following multiple-dose administration in mice and humans.

Huynh C, Brussee JM, Pouzol L, Fonseca M, Meyer Zu Schwabedissen HE, Dingemanse J, Sidharta PN. Huynh C, et al. Among authors: meyer zu schwabedissen he. Biomed Pharmacother. 2021 Dec;144:112363. doi: 10.1016/j.biopha.2021.112363. Epub 2021 Oct 28. Biomed Pharmacother. 2021. PMID: 34794236 Free article. Clinical Trial.

5

The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first-in-class ACKR3/CXCR7 antagonist, ACT-1004-1239.

Huynh C, Dingemanse J, Meyer Zu Schwabedissen HE, Fonseca M, Sidharta PN. Huynh C, et al. Among authors: meyer zu schwabedissen he. Clin Transl Sci. 2024 Jul;17(7):e13883. doi: 10.1111/cts.13883. Clin Transl Sci. 2024. PMID: 39010703 Free PMC article. Clinical Trial.

6

Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers.

Duthaler U, Suenderhauf C, Karlsson MO, Hussner J, Meyer Zu Schwabedissen H, Krähenbühl S, Hammann F. Duthaler U, et al. Br J Clin Pharmacol. 2019 Mar;85(3):626-633. doi: 10.1111/bcp.13840. Epub 2019 Jan 24. Br J Clin Pharmacol. 2019. PMID: 30566757 Free PMC article. Clinical Trial.

7

OATP1B3-1B7 (LST-3TM12) Is a Drug Transporter That Affects Endoplasmic Reticulum Access and the Metabolism of Ezetimibe.

Malagnino V, Duthaler U, Seibert I, Krähenbühl S, Meyer Zu Schwabedissen HE. Malagnino V, et al. Among authors: meyer zu schwabedissen he. Mol Pharmacol. 2019 Aug;96(2):128-137. doi: 10.1124/mol.118.114934. Epub 2019 May 24. Mol Pharmacol. 2019. PMID: 31127008

8

Metamizole is a Moderate Cytochrome P450 Inducer Via the Constitutive Androstane Receptor and a Weak Inhibitor of CYP1A2.

Bachmann F, Duthaler U, Meyer Zu Schwabedissen HE, Puchkov M, Huwyler J, Haschke M, Krähenbühl S. Bachmann F, et al. Among authors: meyer zu schwabedissen he. Clin Pharmacol Ther. 2021 Jun;109(6):1505-1516. doi: 10.1002/cpt.2141. Epub 2021 Jan 19. Clin Pharmacol Ther. 2021. PMID: 33336382 Free PMC article.

9

Cytochrome P450 1A2 is the most important enzyme for hepatic metabolism of the metamizole metabolite 4-methylaminoantipyrine.

Bachmann F, Meyer Zu Schwabedissen HE, Duthaler U, Krähenbühl S. Bachmann F, et al. Among authors: meyer zu schwabedissen he. Br J Clin Pharmacol. 2022 Feb;88(4):1885-1896. doi: 10.1111/bcp.15108. Epub 2021 Nov 7. Br J Clin Pharmacol. 2022. PMID: 34648192 Free PMC article. Clinical Trial.

10

Humanization of SLCO2B1 in Rats Increases rCYP3A1 Protein Expression but Not the Metabolism of Erlotinib to OSI-420.

Rysz M, Schäfer AM, Paloumpis N, Kinzi J, Brecht K, Seibert I, Schmidlin S, In-Albon K, Ricklin D, Meyer Zu Schwabedissen HE. Rysz M, et al. Among authors: meyer zu schwabedissen he. J Pharmacol Exp Ther. 2024 Mar 15;389(1):87-95. doi: 10.1124/jpet.123.001884. J Pharmacol Exp Ther. 2024. PMID: 38448247

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

130 results

Search Page

Filters